Chronic Kidney Diseases

Nephrology
12
Pipeline Programs
18
Companies
21
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
5
1
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
133%
Monoclonal Antibody
133%
Vaccine
133%
+ 19 programs with unclassified modality

Competitive Landscape

17 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
2
Empagliflozin 10 MGPhase 41 trial
Empagliflozin 10 MG then PlaceboPhase 41 trial
Active Trials
NCT06110130Recruiting60Est. Dec 2028
NCT07074418Not Yet Recruiting34Est. Dec 2027
Veloxis Pharmaceuticals
1 program
1
Conversion from IR Tacrolimus to XR TacrolimusPhase 41 trial
Active Trials
NCT04917718UnknownEst. Dec 2024
Biogen
BiogenCAMBRIDGE, MA
2 programs
1
1
Bardoxolone methylPhase 31 trial
Bardoxolone methyl oral capsulePhase 21 trial
Active Trials
NCT04702997Completed81Est. Nov 2021
NCT03749447Terminated270Est. Aug 2023
Providence Therapeutics
1 program
1
Pfizer-BioNTech COVID-19 VaccinePhase 2/3Vaccine1 trial
Active Trials
NCT05022329TerminatedEst. Nov 2022
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
3 programs
2
KBP-5074 0.25 mg tabletPhase 21 trial
ZiltivekimabPhase 2Monoclonal Antibody1 trial
Glucagon infusionN/A1 trial
Active Trials
NCT05056584Completed48Est. Mar 2023
NCT03574363Completed162Est. Aug 2020
NCT03926117Completed264Est. Jun 2020
Lantheus Medical Imaging
1 program
1
Perflutren Lipid microspherePhase 21 trial
Active Trials
NCT03196076CompletedEst. Mar 2021
Tourmaline Bio
Tourmaline BioNY - New York
1 program
1
TOUR006 - 50 MGPhase 21 trial
Active Trials
NCT06362759CompletedEst. Dec 2025
CT
2 programs
2
TQ-B3525Phase 11 trial
domestic polysaccharide superparamagnetic iron oxide nanoparticlePhase 11 trial
Active Trials
NCT05675202UnknownEst. Dec 2023
NCT05045872CompletedEst. Sep 2024
Bayer
BayerLEVERKUSEN, Germany
1 program
Alert-based computerized decision supportN/A1 trial
Active Trials
NCT05342545Completed400Est. May 2025
Ossium Health
Ossium HealthIN - Indianapolis
1 program
Allogeneic, vertebral bone marrow-derived mesenchymal stem cellsN/A1 trial
Active Trials
NCT06752577RecruitingEst. Dec 2031
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Chronic Kidney Disease Registry Platform StudyN/A1 trial
Active Trials
NCT06117852Active Not Recruiting1,927Est. Nov 2028
Verona Pharma
Verona PharmaUK - London
1 program
Kidney ACTionN/A1 trial
Active Trials
NCT05056909Withdrawn0Est. Oct 2024
Abbott
AbbottABBOTT PARK, IL
1 program
LinagliptinN/ASmall Molecule1 trial
Active Trials
NCT02608177Completed3Est. Aug 2018
UP
UCB PharmaBelgium - Brussels
1 program
National Unified Renal Translation Research Enterprise - Chronic Kidney DiseaseN/A1 trial
Active Trials
NCT04084145Active Not Recruiting3,004Est. Dec 2032
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
National Unified Renal Translation Research Enterprise - Chronic Kidney DiseaseN/A
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Non- contrast Enhanced Multiparametric Renal Magnetic ResonanceN/A1 trial
Active Trials
NCT05229263Active Not Recruiting140Est. Dec 2025
CP
Chugai PharmaJapan - Tokyo
1 program
endoscopyN/A1 trial
Active Trials
NCT02539680Terminated18Est. Nov 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Boehringer IngelheimEmpagliflozin 10 MG then Placebo
Boehringer IngelheimEmpagliflozin 10 MG
Veloxis PharmaceuticalsConversion from IR Tacrolimus to XR Tacrolimus
BiogenBardoxolone methyl
Providence TherapeuticsPfizer-BioNTech COVID-19 Vaccine
Tourmaline BioTOUR006 - 50 MG
BiogenBardoxolone methyl oral capsule
Novo NordiskZiltivekimab
Novo NordiskKBP-5074 0.25 mg tablet
Lantheus Medical ImagingPerflutren Lipid microsphere
Chia Tai TianQing Pharmaceutical GroupTQ-B3525
Chia Tai TianQing Pharmaceutical Groupdomestic polysaccharide superparamagnetic iron oxide nanoparticle
Ossium HealthAllogeneic, vertebral bone marrow-derived mesenchymal stem cells
AstraZenecaChronic Kidney Disease Registry Platform Study
BayerAlert-based computerized decision support

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 6,411 patients across 21 trials

NCT07074418Boehringer IngelheimEmpagliflozin 10 MG then Placebo

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

Start: Apr 2026Est. completion: Dec 202734 patients
Phase 4Not Yet Recruiting
NCT06110130Boehringer IngelheimEmpagliflozin 10 MG

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

Start: Feb 2024Est. completion: Dec 202860 patients
Phase 4Recruiting
NCT04917718Veloxis PharmaceuticalsConversion from IR Tacrolimus to XR Tacrolimus

Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus

Start: Aug 2021Est. completion: Dec 2024
Phase 4Unknown
NCT03749447BiogenBardoxolone methyl

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

Start: Mar 2019Est. completion: Aug 2023270 patients
Phase 3Terminated
NCT05022329Providence TherapeuticsPfizer-BioNTech COVID-19 Vaccine

COVID-19 Vaccine Boosters in Patients With CKD

Start: Sep 2021Est. completion: Nov 2022
Phase 2/3Terminated
NCT06362759Tourmaline BioTOUR006 - 50 MG

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

Start: May 2024Est. completion: Dec 2025
Phase 2Completed
NCT04702997BiogenBardoxolone methyl oral capsule

A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)

Start: Feb 2021Est. completion: Nov 202181 patients
Phase 2Completed
NCT03926117Novo NordiskZiltivekimab

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Start: Jun 2019Est. completion: Jun 2020264 patients
Phase 2Completed
NCT03574363Novo NordiskKBP-5074 0.25 mg tablet

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

Start: Apr 2018Est. completion: Aug 2020162 patients
Phase 2Completed
NCT03196076Lantheus Medical ImagingPerflutren Lipid microsphere

Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension

Start: Aug 2017Est. completion: Mar 2021
Phase 2Completed
NCT05675202Chia Tai TianQing Pharmaceutical GroupTQ-B3525

Material Balance Study of TQ-B3525

Start: Jan 2023Est. completion: Dec 2023
Phase 1Unknown
NCT05045872Chia Tai TianQing Pharmaceutical Groupdomestic polysaccharide superparamagnetic iron oxide nanoparticle

Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging

Start: Sep 2021Est. completion: Sep 2024
Phase 1Completed
NCT06752577Ossium HealthAllogeneic, vertebral bone marrow-derived mesenchymal stem cells

Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)

Start: Dec 2024Est. completion: Dec 2031
N/ARecruiting
NCT06117852AstraZenecaChronic Kidney Disease Registry Platform Study

Chronic Kidney Disease Registry Platform Study

Start: Nov 2023Est. completion: Nov 20281,927 patients
N/AActive Not Recruiting
NCT05342545BayerAlert-based computerized decision support

Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus

Start: Dec 2022Est. completion: May 2025400 patients
N/ACompleted
NCT05229263Heidelberg PharmaNon- contrast Enhanced Multiparametric Renal Magnetic Resonance

Multiparametric MRI in Healthy Volunteers and CKD Patients

Start: Nov 2022Est. completion: Dec 2025140 patients
N/AActive Not Recruiting
NCT05056909Verona PharmaKidney ACTion

Kidney AI-enabled Care Transformation

Start: Nov 2022Est. completion: Oct 20240
N/AWithdrawn
NCT05056584Novo NordiskGlucagon infusion

The Role of the Kidneys and Liver in the Elimination of Glucagon

Start: Aug 2020Est. completion: Mar 202348 patients
N/ACompleted
NCT04084145UCB PharmaNational Unified Renal Translation Research Enterprise - Chronic Kidney Disease

National Unified Renal Translation Research Enterprise - Chronic Kidney Disease

Start: Jul 2016Est. completion: Dec 20323,004 patients
N/AActive Not Recruiting
NCT02608177AbbottLinagliptin

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

Start: Nov 2015Est. completion: Aug 20183 patients
N/ACompleted
NCT02539680Chugai Pharmaendoscopy

Intestinal Phosphate Transporter Expression in CKD Patients

Start: Sep 2015Est. completion: Nov 201718 patients
N/ATerminated

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 6,411 patients
18 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)Acute Kidney Injury(16)